Retraction Note: J Exp Clin Cancer Res 39, 146 (2020)
https://doi.org/10.1186/s13046-020-01654-3
The Editor-in-Chief has retracted this article. After publication concerns were raised with respect to the overlap of figures with a previously published article from another author group [1]. Specifically:
Figure 1b, 1c, 1d, 1e and 1f with Figure 1c, 1d, 1e, 1f and 1h of Figure 1 of [1]
Figure 2 with Figure 2 of [1]
Figure 3b and 3c with Figure 3b and 3d of [1]
Figure 4b, 4c and 4d with Figure 4b, 4c and 4d of [1]
Figure 5 with Figure 5 of [1]
Figure 6 with Figure 6 of [1]
Figure 7 with Figure 7 of [1]
The Editor-in-Chief no longer has confidence in the results and conclusions reported. Ming Hong agrees with this retraction. Jacob Clayton, Wildman Yake and Jinke Li have not responded to correspondence from the Publisher about this retraction. The Publisher was not able to obtain a current email address for Selena Lee.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Ming Hong, Email: hongming1986@gzucm.edu.cn.
Jinke Li, Email: j086l791@ku.edu.
Reference
- 1.Zhang T, Li J, Yin F, et al. Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Oncogene. 2017;36:6627–6639. doi: 10.1038/onc.2017.270. [DOI] [PMC free article] [PubMed] [Google Scholar]